Brief: Mustang Bio Announces Final Results From Follicular Lymphoma Cohort Of Single-Institution Phase 1/2 Clinical Trial Of MB-106
15/06/2023 21:07
June 15 (Reuters) - Fortress Biotech Inc FBIO.O :
* MUSTANG BIO ANNOUNCES FINAL RESULTS FROM FOLLICULAR
LYMPHOMA
COHORT OF SINGLE-INSTITUTION PHASE 1/2 CLINICAL TRIAL OF MB-106,
CD20-TARGETED AUTOLOGOUS CAR T THERAPY
* MUSTANG BIO INC - INITIAL DATA FROM ONGOING MULTICENTER
TRIAL
EXPECTED SHORTLY
* MUSTANG BIO INC - 95% OVERALL RESPONSE RATE (ORR) AND 80%
COMPLETE RESPONSE (CR) RATE ACROSS ALL PATIENTS IN STUDY
Source text for Eikon: ID:nGNX9CHTBM
Further company coverage: FBIO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fortress Biotech
See all newsFortress Biotech Inc reports results for the quarter ended June 30 - Earnings Summary
Fortress Biotech Inc expected to post a loss of 20 cents a share - Earnings Preview
Brief: Fortress Biotech And Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $130 Million Series B Financing
Fortress Biotech Q1 net income jumps on PRV sale
Brief: Journey Medical Corporation Secures Contract With Third Major Gpo For Emrosi